real-time news and commentary for investors
Friday, May 25
2012, 4:41 PM
Forest Laboratories (FRX) says it's decided to discontinue the development of apadenoson, its...
Forest Laboratories (FRX) says it's decided to discontinue the development of apadenoson, its experimental agent for cardiovascular imaging procedures. The company had obtained the compound in its $1.3B acquisition last year of Clinical Data, and had previously said it expected to launch the product by 2014. The agent was being tested in a late-stage clinical trial, but the trial was recently terminated. The company failed to give a reason in its filing with the SEC .